Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony zaawansowany rak płuca z mutacją EGFR, który nie można operować
- •Poprzednia terapia osimertynibem w terapii pierwszej lub drugiej linii
- •Stan ogólny pozwalający na leczenie (ECOG 0-1)
- •Chęć i możliwość udzielenia świadomej zgody na udział w badaniu
✗ Disqualifies
- •Rak spowodowany innym niż EGFR uszkodzeniem genetycznym
- •Mutacje EGFR powodujące odporność na osimertynib
- •Nadmierna ekspresja białka HER2 w komórkach raka
- •Jakiekolwiek przeciwwskazania do leczenia osimertynibem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
Maryland Oncology Hematology
Calverton, United States
Massachusetts General Hospital
Boston, United States
Willamette Valley Cancer Institute and Research Center
Eugene, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
NEXT Houston
Houston, United States
NEXT Virginia
Fairfax, United States
Trial contact
Erin Belshaw
Shay Shemesh
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.